CAJ | 학술논문

目的：探讨晚期大肠癌经联合化疗控制后替吉奥维持治疗的临床疗效。方法66例晚期大肠癌患者联合化疗控制瘤体后分成两组,治疗组36例给予替吉奥维持治疗,对照组30例给予随访观察,评估两组的近期疗效﹑无进展生存期及替吉奥的不良反应。结果替吉奥维持治疗36例患者中位PFS 11.2月,对照随访观察组30例患者中位PFS 6.9月。结论晚期大肠癌联合化疗后给予维持治疗可获得较长的PFS,值得进一步研究维持治疗的临床价值。
목적：탐토만기대장암경연합화료공제후체길오유지치료적림상료효。방법66례만기대장암환자연합화료공제류체후분성량조,치료조36례급여체길오유지치료,대조조30례급여수방관찰,평고량조적근기료효﹑무진전생존기급체길오적불량반응。결과체길오유지치료36례환자중위PFS 11.2월,대조수방관찰조30례환자중위PFS 6.9월。결론만기대장암연합화료후급여유지치료가획득교장적PFS,치득진일보연구유지치료적림상개치。
Objective The study aims to investigate the clinical curative effect of S-1 maintenance therapy for advanced colorectal cancer controlled by combination chemotherapy. Methods 66 patients with advanced colorectal cancer were divided into two groups after the tumor of them was controlled by the combination chemotherapy. 36 cases in the treatment group were given S-1 maintenance therapy. And 30 cases in the control group were given the follow-up observation. The short-term efficacy, progression free survival (PFS) of the two groups and adverse reactions of S-1 were evaluated. Results The median PFS time for 36 patients receiving S-1 maintenance therapy was 11.2 months and that of the 30 patients receiving follow-up observation in the control group was 6.9 months. Conclusion Patients with advanced colorectal cancer after combination chemotherapy can obtain longer PFS after being given maintenance therapy. And it is worthwhile to further evaluate the clinical value of maintenance therapy.